

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

March 2016
Volume 19, Number 3

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – Celebrating Pharmacy Awareness Month
- **Drug Update** – Postponed: Filtration of Paclitaxel-nab (ABRAXANE®) Preparations
- **Nursing Practice Update** – Pain and Symptom Management Learning Guide
- **Communities Oncology Network** – Reminder: OSCAR Submission Deadline – 6 April 2016
- **Cancer Drug Manual** – Revised: Brentuximab Vedotin, Carfilzomib, Oxaliplatin, Vemurafenib
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – Revised: CNTEMOZ, ULYBRENTUX, SCPAINLI
- **Website Resources and Contact Information**

EDITOR'S CHOICE

CELEBRATING PHARMACY AWARENESS MONTH

March marks Pharmacy Awareness Month (PAM) in Canada! The PAM 2016 tagline, *Your Hospital Pharmacy Team: Your Trusted Medication Experts*, speaks to the key role that the pharmacy team plays in providing trusted, accessible and comprehensive health care services.

PAM was first developed by the Canadian Society of Hospital Pharmacists (CSHP) in 1990 to increase awareness among health professionals and the public about the evolving roles of pharmacists and pharmacy technicians. This annual event takes place nationally to celebrate the pharmacy profession and to recognize the many ways in which the pharmacy team contributes to the care, health and wellness of patients. PAM provides an opportunity to inform and educate patients and health professionals on the significant contributions that pharmacy has made to patient-centred care.

Take this opportunity to celebrate the profession of pharmacy with your colleagues and participate in PAM activities! Join us and get to know your pharmacy team better. Activities and displays are planned for each BCCA regional cancer centre – stay tuned and be sure to speak with your friendly pharmacy team for more information.

Submitted by: Vian Cheng, BSc(Pharm) and Esther Chan, BSc(Pharm)
BC Cancer Agency Pharmacy Residents 2015-2016

DRUG UPDATE

POSTPONED: FILTRATION OF PACLITAXEL-NAB (ABRAXANE®) PREPARATIONS

The BCCA had planned to mandate the use of 15-micron filters during the drug administration of all paclitaxel-nab preparations effective March 2016. This implementation is now postponed until further notice. For details about the impending filtration requirement, please see the [February issue](#) of the Systemic Therapy Update.

NURSING PRACTICE UPDATE

PAIN AND SYMPTOM MANAGEMENT LEARNING GUIDE

The BCCA Pain and Symptom Management Learning Guide has recently become available to all registered nurses (RNs) and nurse practitioners (NPs) at the BCCA and Communities Oncology Network. Previously, the guide was only available to RNs working with the BCCA Pain and Symptom Management/Palliative Care team through a mandatory clinical orientation process. While the guide will continue to be used for this purpose, RNs and NPs working in other clinical areas may now request access to this learning guide by contacting Isabel Lundie, Administrative Coordinator, Professional Practice Nursing [Email: ilundie@bccancer.bc.ca].

COMMUNITIES ONCOLOGY NETWORK

REMINDER: OSCAR SUBMISSION DEADLINE – 6 APRIL 2016

The 2015/16 fiscal year will end on Thursday, 31 March 2016. To meet the deadlines for external reporting to the Ministry of Health, all claims for drug reimbursement for the fiscal year must be invoiced by 11:59 pm on Wednesday, 6 April 2016 via OSCAR (Online System for Cancer drugs Adjudication and Reimbursement). Any claims invoiced after that date will not be eligible for reimbursement. For more information, please contact oscar@bccancer.bc.ca.

CANCER DRUG MANUAL

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Brentuximab Vedotin Monograph & Handout:

- Name has been revised from brentuximab to brentuximab vedotin to reflect the product as an antibody-drug conjugate

CANCER DRUG MANUAL

Carfilzomib Interim Monograph: (Notice of Compliance granted)

- *Supply and Storage* section – updated with a Canadian supplier
- *Special Precautions, Side Effects, Parenteral Administration and Dosing* sections – updated based on the Canadian drug product monograph

Oxaliplatin Monograph:

- *Cautions, Side Effects and Interactions* sections – added warning on QT-prolongation based on updated safety labelling information in the Canadian drug product monograph

Vemurafenib Monograph & Handout:

- *Special Precautions and Side Effects* section – added information on radiation sensitivity and recall reactions
- *Drug Interactions* section – added digoxin and other P-glycoprotein interactions

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
CNTEMOZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected under Dose Modifications</i>	Therapy for Malignant Brain Tumours Using Temozolomide
ULYBRENTUX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Protocol title clarified</i>	Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab Vedotin
SCPAINLI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and exclusions clarified, tests and treatment sections updated</i>	Extreme Pain Therapy Using Parenteral Lidocaine

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mário de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN BN CONc
 Rob Watt, BSc(Pharm)